Circulating Fibrocytes Prepare the Lung for Cancer Metastasis by Recruiting Ly-6C+ Monocytes Via CCL2

Hendrik W. van Deventer, Daniela A. Palmieri, Qing Ping Wu, Everett C. McCook and Jonathan S. Serody
J Immunol May 1, 2013, 190 (9) 4861-4867; DOI: https://doi.org/10.4049/jimmunol.1202857

Abstract

Fibrocytes are circulating, hematopoietic cells that express CD45 and Col1a1. They contribute to wound healing and several fibrosing disorders by mechanisms that are poorly understood. In this report, we demonstrate that fibrocytes predispose the lung to B16-F10 metastasis by recruiting Ly-6C+ monocytes. To do so, we isolated fibrocytes expressing CD45, CD11b, CD13, and Col1a1 from the lungs of wild type (WT) and Ccr5−/− mice. WT but not Ccr5−/− fibrocytes increased the number of metastatic foci when injected into Ccr5−/− mice (73 ± 2 versus 32 ± 5; p < 0.001). This process was MMP9 dependent. Injection of WT enhanced GFP+ fibrocytes also increased the number of Gr-1Int, CD11b+, and enhanced GFP– monocytes. Like premetastatic-niche monocytes, these recruited cells expressed Ly-6C, CD117, and CD45. The transfer of these cells into Ccr5−/− mice enhanced metastasis (90 ± 8 foci) compared with B cells (27 ± 2), immature dendritic cells (31 ± 6), or alveolar macrophages (28 ± 3; p < 0.05). WT and Ccl2−/− fibrocytes also stimulated Ccl2 expression in the lung by 2.07 ± 0.05- and 2.78 ± 0.36-fold compared with Ccr5−/− fibrocytes (1.0 ± 0.06; p < 0.05). Furthermore, WT fibrocytes did not increase Ly-6C+ monocytes in Ccr2−/− mice and did not promote metastasis in either Ccr2−/− or Ccl2−/− mice. These data support our hypothesis that fibrocytes contribute to premetastatic conditioning by recruiting Ly-6C+ monocytes in a chemokine-dependent process. This work links metastatic risk to conditions that mobilize fibrocytes, such as inflammation and wound repair.

Introduction

Since their discovery in 1994, fibrocytes have been described as circulating, COL1A1-expressing, hematopoietic cells (1). Derived from CD14 monocytes (2), these cells constitute <1% of the adult leukocyte pool. In health, fibrocytes are thought to promote wound healing by migrating into areas of injury and differentiating into activated fibroblasts (3). This mechanism has also been inferred from observations of several fibrosing disorders, including keloid formation (4), posttransplant bronchiolitis obliterans (5, 6), peritoneal fibrosis, and thyroid ophthalmopathy (7). However, there is little data to substantiate this model in vivo.

A role for fibrocytes in tumor promotion has been more difficult to discern. A small number of studies have focused on the ability of fibrocytes to propagate tumor stroma. This stroma is populated with activated fibroblasts, which are characterized by their expression of α smooth muscle actin. This gene is also expressed by fibrocytes in response to TGF-β and other cytokines that promote tumor stromagenesis (8). Thus, fibrocytes can promote tumorigenesis by becoming incorporated into the stroma.

Despite the appeal of this hypothesis, this model is flawed. The small number of circulating fibrocytes likely limits their contribution to the tumor stroma. This observation has already been demonstrated in liver and dermatologic diseases associated with fibrocytes (9). Moreover, the tumor stroma has many other sources of activated fibroblasts (10). This hypothesis also fails to consider other biologic functions connected to fibrocytes. For example, fibrocytes contribute to innate immunity by the expression of antimicrobial factors (11) and adaptive immunity by Ag presentation (12). In short, fibrocytes have numerous functions that might be critical for tumor promotion. Furthermore, these functions may be independent of their ability to be incorporated into the tumor stroma.

This report establishes a new biologic role for fibrocytes as regulators of cell migration. In the process, we also provide experimental evidence that directly links fibrocytes to cancer progression. In our model, circulating fibrocytes prompt an influx of Ly-6C+, Ly-6Glo monocytes into the lung. This influx conditions the lung to make it more vulnerable to the invasion of cancer cells. Our model is consistent with the observations of Kaplan and others who have described the establishment of the premetastatic niche by Ly-6C+monocytes (13). We also show that this process is dependent on CCR2 and CCR5, adding to the preclinical data that establish these chemokine receptors as potential therapeutic targets.

Materials and Methods

Mice and cell lines

C57BL/6J Ccr5−/− have been previously described (14); matrix metalloproteinase 9 knockout mice (Mmp9−/−) were a gift from Dr. Lynn Matrisian. All other mouse strains were purchased from The Jackson Laboratory (Bar Harbor, ME). All animals were housed in pathogen-free conditions. Ccr5−/− × Mmp9−/− mice were produced by crossing F1 progeny of Ccr5−/− and Mmp9−/− mice.

All experiments were conducted using protocols approved by the Institutional Animal Care and Use Committee of the University of North Carolina–Chapel Hill. B16-F10, CT26, and Line 1 cell lines were purchased form American Type Culture Collection (Rockland, MD). Cell lines were verified using short tandem repeat analysis.

In vivo experiments

Pulmonary mesenchymal cells (PMCs) were isolated as described previously (15). Fibrocytes were separated from PMCs using CD45 Miltenyi beads (Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Immature dendritic cells were cultured from bone marrow using GM-CSF (Invitrogen) and B cells were isolated from splenocytes also using B220 beads.

Details for the melanoma metastasis model have been described previously (16). In brief, 1 × 105 fibrocytes in 200 μl PBS were injected via the tail vein. Twenty-four hours later, 7.5 × 105 B16-F10 melanoma cells were injected. Mice were euthanized 14 d later, and metastases were counted after insufflation with Fekete’s destaining solution. Experiments using other cell lines were performed in a similar manner. CT26 cells (1 × 105) were injected into C57BL/6J mice and 2 × 105 Line 1 cells were injected into BALB/c mice. Visualization of tumor nodules was enhanced by insufflation with 15% solution of India ink–PBS followed by storage in Fekete’s solution.

Ex vivo experiments

The formation of enhanced GFP (EGFP) bone marrow chimeric mice has already been described (17). In brief, wild type (WT) mice were irradiated with 950 rad and injected with 3 × 106 bone marrow cells from EGFP transgenic mice. Recipient mice were maintained for 8 wk prior to their use in these studies. Details for flow cytometry and PCR have been described previously (18). Real-time PCR was performed on cDNA synthesized with M-MLV reverse transcriptase (Invitrogen) and random hexamers. Transcript number was measured with SYBR green and an ABI PRISM 7900 real-time RT-PCR system (Applied Biosystems, Foster City, CA). The copy number was normalized against the absolute mRNA amount as measured by Qubit Quantitation Platform (Invitrogen). Abs and primer sequences are given in Supplemental Table I.

Western blotting was performed on FACS-sorted pulmonary cells as previously described (18). The samples were run on a 10% SDS gel before being transferred to nitrocellulose. Primary Abs were diluted to 1:1000, and secondary Abs were diluted to 1:10,000.

Cytospin slides were prepared from a single-cell suspension of CD11b+ pulmonary cells isolated by immunomagnetic beads and resuspended in 0.5% BSA. After Wright–Giemsa staining, differential counts were performed on 500 or more cells by an investigator (H.W.v.D.) blinded to the treatment.

Statistics

Unless otherwise stated, data are presented as the mean of measurements taken from three or more separate experiments. Statistical error for these means is presented as ± 1 SEM. Confidence intervals were determined using a 60% trimmed mean. The p values were determined by Mann–Whitney U test and values less than 0.05 were considered significant. The Bonferroni correction was applied to experiments involving multiple comparisons.

Results

WT fibrocytes increase metastasis in Ccr5−/− mice

PMCs can be isolated by culturing a single-cell suspension from the lung and harvesting the adherent cells in two to three weeks. The resultant cells increase metastasis in Ccr5−/− mice when injected prior to the injection B16-F10 melanoma cells (17). This observation is not limited to the B16-F10 cell line. As demonstrated in Fig. 1A, PMCs also increased metastasis in WT mice when transferred prior to the i.v. injection of CT26 cells (12.4 ± 1.9 versus 96.8 ± 6.4; p < 0.001) or Line 1 cells (1.3 ± 0.4 versus 7.9 ± 2.1; p < 0.001).

FIGURE 1.
FIGURE 1.

Characterization and isolation of fibrocytes. (A) Injection of WT pulmonary mesenchymal cells increases metastases with CT26 and Line 1 tumor cells. The graph shows the number of metastatic foci in BALB/c mice injected with 4 × 105 pulmonary mesenchymal cells (PMCs; striped bars) compared with PBS-injected controls (solid bars). The graph on the left demonstrates a 7.8-fold increase in metastasis after injection with 1 × 105 CT26 cells (n = 20). The graph on the right shows a 6.2-fold increase after an injection with 2 × 105 Line 1 cells (n = 22). (B) CD45+ fibrocytes can be isolated using immunomagnetic bead selection. Pulmonary mesenchymal cells were isolated from minced lung cultures as described. These cells were incubated with CD45 immunomagnetic beads and selected with Miltenyi magnetic columns. Representative dot plots are shown for cells prior to selection (left), CD45 selected cells (center), and flow through cells (right; n = 4). (C) CD45+ PMCs are phenotypically consistent with fibrocytes. Flow cytometry was performed on PMCs for the indicated markers. Representative histograms are shown for CD45+ cells (solid gray) and isotype control (black line). (D) CD45+ fibrocytes originate in the bone marrow. WT bone marrow chimeric mice were formed by injecting 3 × 106 bone marrow cells from EGFP transgenic mice into irradiated WT mice. Six to eight weeks later, the lungs were harvested and PMCs were isolated using the standard 2-wk protocol. The cells were then assessed by flow cytometry. The dot plot on the left shows PMCs characterized by forward scatter and CD45 expression. The histogram on the top right shows the percentage of EGFP+ cells taken from the CD45+ PMCs (R2). The histogram on the bottom shows EGFP+ cells taken from the CD45− PMCs (R3). The unfilled black line is EGFP expression for WT mice injected with WT (non-EGFP) marrow (n = 8).

PMCs can be separated by CD45 expression into CD45− fibroblasts and CD45+ fibrocytes. We used this distinction to isolate fibrocytes with immunomagnetic beads (Fig. 1B). The isolated cells expressed CD11b, CD13, and collagen, type 1, α 1 (Col1A1), consistent with a fibrocyte phenotype (Fig. 1C). The purity of this isolate was 91% ± 3.0% based on Col1A1 expression. The hematopoietic lineage of these fibrocytes was then confirmed by creating chimeric mice with EGFP transgenic bone marrow (Fig. 1C); 90.1 ± 0.2% of the CD45+ fibrocytes isolated from the chimeric mice expressed EGFP, indicating that these cells were derived from bone marrow precursors.

To determine whether fibrocytes were the subset of PMCs that mediated pulmonary metastases, we transferred 1 × 105 fibrocytes into Ccr5−/− mice prior to the injection of the B16-F10 cells. These mice developed an equivalent number of metastases (73 ± 2) as WT mice injected with WT fibrocytes (85 ± 5) and WT mice that were not treated with fibrocytes (69 ± 4; Fig. 2A). The size and distribution of the metastatic colonies were similar with all three treatments; the only difference was the number of metastases (Supplemental Fig. 1). All three of these groups had significantly more pulmonary metastases than uninjected Ccr5−/− mice (49 ± 3; p < 0.01) or mice injected with Ccr5−/− fibrocytes (32 ± 5; p < 0.001). CD45− fibroblasts, however, did not increase metastasis compared with fibrocytes (72 ± 10 versus 113 ± 4; p < 0.002; Fig. 2B). Therefore, these data indicate that the fraction of PMCs promoting lung metastases is the CD45+ fibrocyte fraction.

FIGURE 2.
FIGURE 2.

WT CD45+ fibrocytes increased metastasis in Ccr5−/− mice via Mmp9. (A) Bar graphs depicting the number of metastases in WT and Ccr5−/− (R5) mice following the injection of 1 × 105 WT or Ccr5−/− fibrocytes (Fcyte); 7.5 × 105 B16-F10 melanoma cells were injected i.v. 24 h after fibrocytes. Metastases were counted 2 wk later (n = 50). (B) Bar graphs depicting metastasis in Ccr5−/− mice (left) and Ccr5−/− mice following injection with either 1 × 105 WT fibroblasts (Fblasts) or fibrocytes (Fcytes; n = 26). (C) Bar graphs showing metastasis in Ccr5−/− and Mmp9−/− (M9) mice following injection with WT or Mmp9−/− fibrocytes (n = 92). (D) Bar graph showing metastasis in mice without fibrocyte injection. WT mice (solid black) had significantly more metastases than Ccr5−/−, Mmp9−/− or the double knockout Mmp9−/− × Ccr5−/− (checkerboard; n = 47).

WT fibrocytes promote metastasis via MMP9

WT PMCs increase metastasis by inducing MMP9 (16). To determine whether fibrocytes promote metastasis by an MMP9-dependent mechanism, we transferred WT fibrocytes into Mmp9−/− mice. As hypothesized, pulmonary metastases were not increased in Mmp9−/− mice as they were in Ccr5−/− mice (43 ± 2 versus 96 ± 6; p < 0.01; Fig. 2C, Supplemental Fig. 1).

These data suggest that CCR5 and MMP9 are part of the same prometastatic pathway. We looked for the potential additive benefit of inhibiting both CCR5 and MMP9 by crossing Mmp9−/− mice with Ccr5−/− mice. As shown in Fig. 2D, metastasis in the double knockout was not inhibited more than either Ccr5−/− or Mmp9−/− mice (48 ± 2 versus 51 ± 3 versus 37 ± 3; p = NS). All three of these groups had fewer metastases than did the control WT mice (72 ± 6; p < 0.05). Therefore, our data indicated that fibrocytes were critical to the promotion of pulmonary metastases and that this process required MMP9 and CCR5, which function via a cis-mediated mechanism.

WT fibrocytes recruit Ly-6C+, Ly-6Glow monocytic cells

Next, we sought the mechanism by which fibrocytes increase pulmonary metastases. Previous work suggested that WT PMCs induced the migration of CD11b+ cells into the lung. We reexamined this finding by injecting EGFP+ fibrocytes from WT and Ccr5−/− mice into Ccr5−/− animals. This design allowed us to exclude the injected fibrocytes by gating on the EGFP− cells. As before, WT EGFP+ fibrocytes induced a statistically significant increase in CD11b+ cells in the lung (p < 0.02; Fig. 3A). No such increase was found in CD11b− cells after the injection of fibrocytes. Injection of Ccr5−/− fibrocytes failed to increase CD11b+ or CD11b− cells.

FIGURE 3.
FIGURE 3.

WT fibrocytes recruited Ly-6+, Ly-6Glo cells in Ccr5−/− mice. (A) CD11b+ cells were increased in Ccr5−/− mice 24 h after the injection of WT EGFP+ fibrocytes. Dot plot shows gating strategy for calculating CD11b+ cell number. The bar graph shows the fold increases of CD11b+ (black bars) and CD11b– (striped; n = 22). (B) Gating strategy for the identification of CD11b+ cells after injection with WT fibrocytes. The top row of dot plots were stained with isotype controls; the bottom row plots were stained with CD115, F4/80, CD11c, and Gr-1. (C) Bar graphs depicting fold induction of cell subpopulations following injection with Ccr5−/− (striped) or WT (solid) fibrocytes. Significant fold induction was seen in only monocytic MDSCs (n = 20). (D) Dot plots from Ccr5−/− mice following the injection of Ccr5−/− (center) or WT (right) fibrocytes. Ly-6C+, Ly-6G− were significantly increased after injection of WT cells. (E) Differential percentages of CD11b+ cells as detected on cytospin preparations. All differentials performed on CD11b+ cells from Ccr5−/− mice after injection with WT fibrocytes (left), Ccr5−/− fibrocytes (center) or no fibrocytes (right; n = 24).

Flow cytometry was then used to identify the following CD11b+ cells: monocytes, macrophages, dendritic cells, granulocytic (Gr-1Hi) myeloid derived suppressor cells (MDSCs), and monocytic (Gr-1Int) MDSCs (Fig. 3B). All other CD11b+ cells were labeled as myeloid cells, not otherwise specified (NOS). Using this approach, the monocytic MDSC was the only population significantly increased by WT but not Ccr5−/− fibrocytes (p < 0.02; Fig. 3C).

Because Gr-1 is a nonspecific marker for myeloid cells, the Gr-1Int population was analyzed further with Ly-6C and Ly-6G Abs. As shown in Fig. 3D, WT fibrocytes did not increase the percentage of Ly-6G+ cells (13.6 ± 1.1 versus 13.3 ± 2.5%; p = NS). However, Ly-6C+, Ly-6Glow cells were significantly increased (17.0 ± 2.0 versus 11.7 ± 2.2%; p < 0.01) after the injection of WT fibrocytes. These flow cytometry results were corroborated by performing differential counts on cytospin preparations of the CD11b+ cells. Monocytes were more prevalent in mice injected with WT fibrocytes compared with the controls (33.2 ± 1.3% versus 25.2 ± 3.0% versus 19.6 ± 1.1%; p < 0.05; Fig. 3E). From these data, we concluded that WT fibrocytes enhanced the recruitment of Ly-6C+, Ly-6Glow monocytes into the lung.

Ly-6C+, Ly-6Glow monocytic cells are consistent with premetastatic monocytes

The premetastatic niche is formed by monocytes characterized by the expression of CD11b, Ly-6C, CD45, CD117, and Itga4 (19). As demonstrated above, fibrocytes recruited monocytes that expressed CD11b and Ly-6C. These monocytes also expressed CD45, CD117, but not CD11c (Fig. 4A). The presence of Itga4 but not Mmp9 was shown by Western blotting applied to monocytes isolated from the lungs of fibrocyte-injected mice (Fig. 4B).

FIGURE 4.
FIGURE 4.

Ly-6C+, Ly-6Glo cells recruited by fibrocytes promoted metastasis. (A) Flow cytometric analysis of Ly-6Glo, Ly-6C+ cells. Gating strategy is on the left; histograms for CD45, CD11c, and CD117 are given on the right (n = 5). (B) Western blot analysis of Ly-6Glo, Ly-6C+ cells isolated from Ccr5−/− mice by flow sorting following injection with WT fibrocytes. (C) Experimental schema for defining function of Ly-6C+ monocytes. Ly-6C+ cells were isolated from Ccr5−/− (R5) mice 24 h after fibrocyte injection and transferred into R5 mice. Tumor cells were injected within 4 h of monocyte injection. (D) Bar graph shows metastasis in Ccr5−/− mice injected with Ccr5−/− fibrocytes or 5 × 106 WT B cells, 1 × 106 WT immature dendritic cells (iDCs), 2 × 105 WT Ly-6C+ monocytes, or WT fibrocytes (n = 42). (E) Experimental schema for the depletion Gr-1 cells. Gr-1 or Ly-6G Ab was given on days −2, , 0, and 2 in relationship to the i.v. injection of B16 F10 cells (day zero). Fibrocytes (1 × 105) were given on day −1; flow cytometry was performed on day 3. (F) Representative dot plots of pulmonary cells from mice treated with either Gr-1 or Ly-6G Ab. The graph on the left includes all cells (excluding debris by FSC/SSC); the graph on the right represents only CD11b+ cells. (G) Bar graph displaying the number of metastasis in mice treated with Gr-1 (n = 15) or Ly-6G (n = 31) Ab. Untreated Ccr5−/− mice (black) had statistically fewer metastases than all other groups. There were no significant differences in Ccr5−/− mice injected with WT fibrocytes.

The defining property of premetastatic monocytes is their capacity to promote metastasis. This ability was tested by isolating Ly-6C+ cells from Ccr5−/− mice injected with WT fibrocytes and then transferring 2 × 105 of these cells into mice that had not received fibrocytes (Fig. 4C). As shown in Fig. 4D, fibrocyte-recruited Ly-6C+ monocytes significantly increased metastasis in Ccr5−/− mice whereas B cells and immature dendritic cells did not (90 ± 8 versus 26 ± 2 and 31 ± 6 respectively; p < 0.01).

The importance of Ly-6C+ monocytes in this model was further strengthened by depleting the Ly-6G++ cells. These cells could be depleted from the lung with the Ly-6G Ab or with the Gr-1 Ab (18) (Fig. 4E, 4F). Depletion of these cells with either Ab had no effect on the fibrocytes’ ability to increase metastasis (Fig. 4G). Therefore, the promotion of metastasis by fibrocytes was not dependent on the recruitment of Ly-6G++ cells. Instead, the prometastatic effect of fibrocytes was limited to their influence on the population of Ly-6C+ myeloid cells.

Ly-6C+ cells are recruited by CCL2-CCR2 axis

Next, we evaluated the fibrocytes’ dependence on Ly-6C+ cells in the promotion of lung metastasis. Ab depletion of the Ly-6C+ cells is not possible because of the ubiquitous expression of this protein. However, the migration of Ly-6C+ monocytes can be inhibited by blocking CCR2. In the Ccr2−/− mouse, injection of WT fibrocytes did not increase the number of Ly-6C+ cells in the lung (5.8 ± 0.6 × 105 versus 7.1 ± 2.4 × 105 cells; p = NS; Fig. 5A). The only significant increase in cell number came after the injection of WT fibrocytes into Ccr5−/− mice (17.3 ± 0.2 × 105 cells; p < 0.05). The percentage of monocytes was also not increased in the Ccr2−/− mice as measured by differential counts of CD11b+ cells recognized on cytospin slides (22.7 ± 0.7% versus 22.7 ± 2.2%; Fig. 5B).

FIGURE 5.
FIGURE 5.

Fibrocytes recruited premetastatic monocytes via CCR2. (A) Bar graphs depicting total number of cells for each subpopulation following the injection with Ccr5−/− (R5), Ccr2−/− (R2), or WT fibrocytes. Significant increase was seen in monocytic MDSCs only. (B) Pie graphs showing differential percentages of CD11b+ cells as detected on cytospin preparations. All differentials performed on CD11b+ cells from Ccr2−/− mice after injection with WT (top) or Ccr5−/− fibrocytes (bottom). (C) Bar graph depicting fold increase in Ccl2 mRNA expression in Ccr5−/− mice following injection with WT, Ccl2−/−, or Ccr5−/− fibrocytes (n = 16). (D) Bar graph representing lung metastasis in Ccr5−/− or Ccr2−/− mice injected with WT, Ccr2−/−, or Ccr5−/− fibrocytes (n = 72). (E) Bar graph showing the number of metastases in Ccr5−/− or Ccl2−/− after the injection of WT or Ccl2−/−fibrocytes (Fcyte; n = 70).

If the recruitment of Ly-6C+ myeloid cells was critical to the ability of fibrocytes to enhance metastasis, then fibrocytes should not increase metastasis in the Ccr2−/− mouse. As expected, WT, Ccr2−/−, or Ccr5−/− fibrocytes did not increase in metastasis in Ccr2−/− mice (Fig. 5C). Once again, the size and distribution of the metastatic colonies was substantially different (Supplemental Fig. 2). These results confirmed the requisite role of the migration of CCR2-expressing Ly-6C+ cells in this process.

The predominant ligand for CCR2 is CCL2. In our model, CCL2 could be generated by migrating fibrocytes or by the surrounding pulmonary stroma. To answer this question, Ccl2 was measured in the lung of Ccr5−/− mice before and after injection with WT and Ccl2−/− fibrocytes. Using real-time PCR, WT and Ccl2−/− fibrocytes increased Ccl2 expression by 2.07 ± 0.05-fold and 2.78 ± 0.36-fold, respectively (p = NS). Both were significantly greater than baseline expression of Ccl2 (1.0 ± 0.06; p < 0.05). These results suggested that Ccl2 induction by fibrocytes was not cell intrinsic because fibrocytes lacking Ccl2 induced similar levels of the chemokine in the lung.

The importance of fibrocyte-generated CCL2 on metastasis was tested by injecting Ccr5−/− mice with WT and Ccl2−/− fibrocytes. As shown in Fig. 5D, metastasis was increased in Ccr5−/− mice by the injection of WT and Ccl2 −/− fibrocytes compared with control (75 ± 12, 76 ± 6, 45 ± 6; p < 0.05). In contrast, WT and Ccl2−/− fibrocytes did not increase metastasis in Ccl2−/− mice (52 ± 6, 53 ± 13) compared with Ccl2−/− mice that had not received fibrocytes (51 ± 7). All three groups had fewer metastases than did Ccr5−/− mice injected with WT fibrocytes (96 ± 5; p ≤ 0.02). These results indicate that the injection of fibrocytes mediates the expression of CCL2 by pulmonary cells.

Discussion

By adoptively transferring WT fibrocytes into Ccr5−/− mice, this report provides confirmation that fibrocytes promote lung metastasis. We intentionally injected fibrocytes before injecting tumor cells. This “premetastatic” model allowed us to study changes induced by the fibrocytes that were not influenced by local tumor. As a result, we were able to show that fibrocytes promoted metastasis by recruiting Ly-6C+ monocytes. Therefore, our data suggest a new function for fibrocytes as regulators of cellular migration.

Fibrocytes have been described in precancerous lesions and in the peritumoral stroma (20, 21). Tumor stroma, however, has significantly reduced numbers of fibrocytes but increased numbers of myofibroblasts. These observational studies assumed the increase in myofibroblasts was due to the transition of fibrocytes to activated fibroblasts. However, these studies were correlative and ignored the predominant sources of tumor-associated fibroblasts. Pericytes, adipocytes, and epithelial cells are all capable of transdifferentiating into stromal cells (22). Bone marrow mesenchymal cells also contribute to the myofibroblast pool (23). Given the large number of cells capable of generating stromal cells, the overall contribution of a small population of migrating fibrocytes could be considered inconsequential. Although the transition from fibrocyte to fibroblast is well documented, incorporation into the stroma might not be their primary mechanism of promoting disease. Our model would add additional complexity to the interpretations of data from these older studies by demonstrating that fibrocytes recruit immunosuppressive myeloid cells to the lung. Such a function would distinguish these cells from other fibroblast precursors.

Premetastatic niches are clusters of bone marrow–derived cells that facilitate the invasion and survival of circulating tumor cells (24). Initially described by Kaplan et al. (13) and later confirmed by several additional investigators, the cells of this niche express CD11b+ (25), Gr-1+ (26), Itga4 (13), CD133, CD34, cKit (CD117), and VLA4 (19). This description is consistent with the Ly-6C+ monocytes recruited by fibrocytes described in the current work. Furthermore, adoptive transfer of these cells established their functional capacity as premetastatic promoters of metastasis.

Experimental evidence for the creation of premetastatic niches is growing. Premetastatic infiltration by monocytes has been described in models of pancreatic (27) and breast cancer (28). Mechanisms underlying the creation of such niches are also beginning to emerge (29), (25), (30), (31). The predominant mechanism of monocyte recruitment in this study was the induction of CCL2. This chemokine has been associated with poorer outcomes in several cancers, including myeloma, breast cancer, and prostate cancer (30). The receptor, CCR2, promotes invasion of myeloid cells after treatment, which creates a greater risk of relapse (32). Polymorphisms that increase CCR2 expression are associated with a greater risk of death in prostate (33) and gastric cancer (34). In the murine metastasis models, Ccl2 has been implicated in the influx of Gr-1+ monocytes in pulmonary metastasis, but not primary mammary tumors in mice. Blockade of Ccl2 inhibits these inflammatory monocytes and prolongs survival (35).

CCL2 can also contribute to the promotion of metastasis by inducing the expression of MMP9 (36). This metalloproteinase is required for the formation of premetastatic niche (37) and for the induction of angiogenesis (38). Our model was also dependent on the expression of MMP9. Together, these signals can establish a positive feedback loop. MMP9 contributes to the recruitment of additional monocytes in a cathepsin-L–dependent manner (39), and CCL2 recruits additional fibrocytes (40). These mechanisms would explain why small numbers of fibrocytes have such profound effects on metastasis.

These data could help to clarify aspects of tumor biology that are poorly understood. For example, several studies have suggested that surgery could have prometastatic effects (41). Peak mobilization of fibrocytes occurs between 3 and 7 d after wound formation (42). These circulating fibrocytes could subsequently condition the stroma for cancer cells emigrating from stem cell niches in the bone marrow. Although this mechanism has not been studied in cancer patients, a similar phenomenon has been documented for endothelial progenitor cells (43).

Our data suggest means of interrupting this pathway, which could create a new means of preventing metastasis. Our work has focused on decreasing fibrocyte migration through the chemokine pathways. Fibrocyte migration has also been decreased by inhibition of MTOR (44), the angiotensin II type 1 receptor (45), Kcs3.1K+ channels (46) or CXCR4 (47). Inhibition of fibrocytes and monocytes might also be possible through the development of dual CCR5/CCR2 inhibitors (48).

In summary, we have presented a mechanism by which fibrocytes can prepare the pulmonary stroma for metastasis by recruiting Ly-6C+, Ly-6Glow monocytes through the induction of CCL2. The interactions among fibrocytes, monocytes, and cancer cells depend on CCR5, CCR2, and MMP9. This work has implications for conditions that promote fibrocyte migration, such as surgery, and it provides a rationale for novel combinations of currently existing therapeutics.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Samuel Middleton for assistance in preparing the figures.

Footnotes

  • This work was supported by American Cancer Society 118750-RSG-10-025-01-CSM (to H.W.v.D.) and National Institutes of Health S-P50-CA58223-19A1 (to J.S.S.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    EGFP
    enhanced GFP
    PMC
    pulmonary mesenchymal cell
    WT
    wild type.

  • Received October 12, 2012.
  • Accepted February 20, 2013.

References

  1. ↵
    1. Bucala R.,
    2. L. A. Spiegel,
    3. J. Chesney,
    4. M. Hogan,
    5. A. Cerami
    . 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1: 71–81.
    OpenUrlPubMed
  2. ↵
    1. Bucala R.
    2012. Review Series – Inflammation & fibrosis fibrocytes and fibrosis. QJM 105: 505–508.
    OpenUrlFREE Full Text
  3. ↵
    1. Quan T. E.,
    2. S. Cowper,
    3. S.-P. Wu,
    4. L. K. Bockenstedt,
    5. R. Bucala
    . 2004. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 36: 598–606.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Iqbal S. A.,
    2. G. P. Sidgwick,
    3. A. Bayat
    . 2012. Identification of fibrocytes from mesenchymal stem cells in keloid tissue: a potential source of abnormal fibroblasts in keloid scarring. Arch. Dermatol. Res. 304: 665–671.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Todd J. L.,
    2. S. M. Palmer
    . 2011. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 140: 502–508.
    OpenUrlCrossRefPubMed
  6. ↵
    1. LaPar D. J.,
    2. M. D. Burdick,
    3. A. Emaminia,
    4. D. A. Harris,
    5. B. A. Strieter,
    6. L. Liu,
    7. M. Robbins,
    8. I. L. Kron,
    9. R. M. Strieter,
    10. C. L. Lau
    . 2011. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann. Thorac. Surg. 92: 470–477, discussion 477.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gillespie E. F.,
    2. K. I. Papageorgiou,
    3. R. Fernando,
    4. N. Raychaudhuri,
    5. K. P. Cockerham,
    6. L. K. Charara,
    7. A. C. P. Goncalves,
    8. S.-X. Zhao,
    9. A. Ginter,
    10. Y. Lu,
    11. et al
    . 2012. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J. Clin. Endocrinol. Metab. 97: E740–E746.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hong K. M.,
    2. J. A. Belperio,
    3. M. P. Keane,
    4. M. D. Burdick,
    5. R. M. Strieter
    . 2007. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor γ. J. Biol. Chem. 282: 22910–22920.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Higashiyama R.,
    2. S. Nakao,
    3. Y. Shibusawa,
    4. O. Ishikawa,
    5. T. Moro,
    6. K. Mikami,
    7. H. Fukumitsu,
    8. Y. Ueda,
    9. K. Minakawa,
    10. Y. Tabata,
    11. et al
    . 2011. Differential contribution of dermal resident and bone marrow-derived cells to collagen production during wound healing and fibrogenesis in mice. J. Invest. Dermatol. 131: 529–536.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kalluri R.,
    2. M. Zeisberg
    . 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6:392–401.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kisseleva T.,
    2. M. von Köckritz-Blickwede,
    3. D. Reichart,
    4. S. M. McGillvray,
    5. G. Wingender,
    6. M. Kronenberg,
    7. C. K. Glass,
    8. V. Nizet,
    9. D. A. Brenner
    . 2011. Fibrocyte-like cells recruited to the spleen support innate and adaptive immune responses to acute injury or infection. J. Mol. Med. 89: 997–1013.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chesney J.,
    2. M. Bacher,
    3. A. Bender,
    4. R. Bucala
    . 1997. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc. Natl. Acad. Sci. USA 94: 6307–6312.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kaplan R. N.,
    2. R. D. Riba,
    3. S. Zacharoulis,
    4. A. H. Bramley,
    5. L. Vincent,
    6. C. Costa,
    7. D. D. MacDonald,
    8. D. K. Jin,
    9. K. Shido,
    10. S. A. Kerns,
    11. et al
    . 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820–827.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kuziel W. A.,
    2. T. C. Dawson,
    3. M. Quinones,
    4. E. Garavito,
    5. G. Chenaux,
    6. S. S. Ahuja,
    7. R. L. Reddick,
    8. N. Maeda
    . 2003. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167: 25–32.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Schüler T.,
    2. S. Körnig,
    3. T. Blankenstein
    . 2003. Tumor rejection by modulation of tumor stromal fibroblasts. J. Exp. Med. 198: 1487–1493.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. van Deventer H. W.,
    2. Q. P. Wu,
    3. D. T. Bergstralh,
    4. B. K. Davis,
    5. B. P. O’Connor,
    6. J. P. Ting,
    7. J. S. Serody
    . 2008. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. Am. J. Pathol. 173: 253–264.
    OpenUrlCrossRefPubMed
  17. ↵
    1. van Deventer H. W.,
    2. W. O’Connor Jr..,
    3. W. J. Brickey,
    4. R. M. Aris,
    5. J. P. Ting,
    6. J. S. Serody
    . 2005. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 65: 3374–3379.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. van Deventer H. W.,
    2. J. E. Burgents,
    3. Q. P. Wu,
    4. R. M. Woodford,
    5. W. J. Brickey,
    6. I. C. Allen,
    7. E. McElvania-Tekippe,
    8. J. S. Serody,
    9. J. P. Ting
    . 2010. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 70: 10161–10169.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Peinado H.,
    2. S. Lavotshkin,
    3. D. Lyden
    . 2011. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21: 139–146.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Barth P. J.,
    2. A. Ramaswamy,
    3. R. Moll
    . 2002. CD34(+) fibrocytes in normal cervical stroma, cervical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cervix uteri. Virchows Arch. 441: 564–568.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Barth P. J.,
    2. T. Schenck zu Schweinsberg,
    3. A. Ramaswamy,
    4. R. Moll
    . 2004. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch. 444: 231–234.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Xouri G.,
    2. S. Christian
    . 2010. Origin and function of tumor stroma fibroblasts. Semin. Cell Dev. Biol. 21: 40–46.
    OpenUrlCrossRefPubMed
  23. ↵
    1. De Boeck A.,
    2. K. Narine,
    3. W. De Neve,
    4. M. Mareel,
    5. M. Bracke,
    6. O. De Wever
    . 2010. Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol. 46: 336–342.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Condeelis J.,
    2. J. W. Pollard
    . 2006. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263–266.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Hiratsuka S.,
    2. A. Watanabe,
    3. H. Aburatani,
    4. Y. Maru
    . 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8: 1369–1375.
    OpenUrlCrossRefPubMed
  26. ↵
    1. McGovern M.,
    2. R. Voutev,
    3. J. Maciejowski,
    4. A. K. Corsi,
    5. E. J. Hubbard
    . 2009. A “latent niche” mechanism for tumor initiation. Proc. Natl. Acad. Sci. USA 106: 11617–11622.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Clark C. E.,
    2. S. R. Hingorani,
    3. R. Mick,
    4. C. Combs,
    5. D. A. Tuveson,
    6. R. H. Vonderheide
    . 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67: 9518–9527.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Yang L.,
    2. J. Huang,
    3. X. Ren,
    4. A. E. Gorska,
    5. A. Chytil,
    6. M. Aakre,
    7. D. P. Carbone,
    8. L. M. Matrisian,
    9. A. Richmond,
    10. P. C. Lin,
    11. H. L. Moses
    . 2008. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23–35.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Gil-Bernabé A. M.,
    2. Š. Ferjančič,
    3. M. Tlalka,
    4. L. Zhao,
    5. P. D. Allen,
    6. J. H. Im,
    7. K. Watson,
    8. S. A. Hill,
    9. A. Amirkhosravi,
    10. J. L. Francis,
    11. et al.
    2012. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119:3164–3175.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Craig M. J.,
    2. R. D. Loberg
    . 2006. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev. 25: 611–619.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Grange C.,
    2. M. Tapparo,
    3. F. Collino,
    4. L. Vitillo,
    5. C. Damasco,
    6. M. C. Deregibus,
    7. C. Tetta,
    8. B. Bussolati,
    9. G. Camussi
    . 2011. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71: 5346–5356.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Nakasone E. S.,
    2. H. A. Askautrud,
    3. T. Kees,
    4. J.-H. Park,
    5. V. Plaks,
    6. A. J. Ewald,
    7. M. Fein,
    8. M. G. Rasch,
    9. Y.-X. Tan,
    10. J. Qiu,
    11. et al
    . 2012. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21: 488–503.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Kucukgergin C.,
    2. F. K. Isman,
    3. B. Cakmakoglu,
    4. O. Sanli,
    5. S. Seckin
    . 2012. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 31: 1418–1424.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Gawron A. J.,
    2. A. J. Fought,
    3. J. Lissowska,
    4. W. Ye,
    5. X. Zhang,
    6. W. H. Chow,
    7. L. E. Beane Freeman,
    8. L. Hou
    . 2011. Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand. J. Gastroenterol. 46: 333–340.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Qian B. Z.,
    2. J. Li,
    3. H. Zhang,
    4. T. Kitamura,
    5. J. Zhang,
    6. L. R. Campion,
    7. E. A. Kaiser,
    8. L. A. Snyder,
    9. J. W. Pollard
    . 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222–225.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Richardson V. J.
    2010. Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int. J. Immunopathol. Pharmacol. 23: 715–726.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Hiratsuka S.,
    2. K. Nakamura,
    3. S. Iwai,
    4. M. Murakami,
    5. T. Itoh,
    6. H. Kijima,
    7. J. M. Shipley,
    8. R. M. Senior,
    9. M. Shibuya
    . 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289–300.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Pollard J. W.
    2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4: 71–78.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Sun M.,
    2. M. Chen,
    3. Y. Liu,
    4. M. Fukuoka,
    5. K. Zhou,
    6. G. Li,
    7. F. Dawood,
    8. A. Gramolini,
    9. P. P. Liu
    . 2011. Cathepsin-L contributes to cardiac repair and remodelling post-infarction. Cardiovasc. Res. 89: 374–383.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Liao W. T.,
    2. H. S. Yu,
    3. J. L. Arbiser,
    4. C. H. Hong,
    5. B. Govindarajan,
    6. C. Y. Chai,
    7. W. J. Shan,
    8. Y. F. Lin,
    9. G. S. Chen,
    10. C. H. Lee
    . 2010. Enhanced MCP-1 release by keloid CD14+ cells augments fibroblast proliferation: role of MCP-1 and Akt pathway in keloids. Exp. Dermatol. 19: e142–e150.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Demicheli R.,
    2. M. W. Retsky,
    3. W. J. M. Hrushesky,
    4. M. Baum
    . 2007. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat. Clin. Pract. Oncol. 4: 699–710.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Mori L.,
    2. A. Bellini,
    3. M. A. Stacey,
    4. M. Schmidt,
    5. S. Mattoli
    . 2005. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp. Cell Res. 304: 81–90.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Laing A. J.,
    2. J. P. Dillon,
    3. E. T. Condon,
    4. J. T. Street,
    5. J. H. Wang,
    6. A. J. McGuinness,
    7. H. P. Redmond
    . 2007. Mobilization of endothelial precursor cells: systemic vascular response to musculoskeletal trauma. J. Orthop. Res. 25: 44–50.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Mehrad B.,
    2. M. D. Burdick,
    3. R. M. Strieter
    . 2009. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 41: 1708–1718.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Sakai N.,
    2. T. Wada,
    3. K. Matsushima,
    4. R. Bucala,
    5. M. Iwai,
    6. M. Horiuchi,
    7. S. Kaneko
    . 2008. The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J. Hypertens. 26: 780–790.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Cruse G.,
    2. S. R. Singh,
    3. S. M. Duffy,
    4. C. Doe,
    5. R. Saunders,
    6. C. E. Brightling,
    7. P. Bradding
    . 2011. Functional KCa3.1 K+ channels are required for human fibrocyte migration. J. Allergy Clin. Immunol. 128: 1303–1309, e2.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Song J. S.,
    2. C. M. Kang,
    3. H. H. Kang,
    4. H. K. Yoon,
    5. Y. K. Kim,
    6. K. H. Kim,
    7. H. S. Moon,
    8. S. H. Park
    . 2010. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp. Mol. Med. 42: 465–472.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Zhao Q.
    2010. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol. 88: 41–55.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section